Today: 12 June 2026
Browse Category

NYSE:LLY 5 January 2026 - 12 January 2026

Nvidia stock wobbles after $1B Eli Lilly AI lab plan as CPI and TSMC loom

Nvidia stock wobbles after $1B Eli Lilly AI lab plan as CPI and TSMC loom

Nvidia and Eli Lilly will invest $1 billion over five years in a joint research lab in the San Francisco Bay Area, aiming to use Nvidia’s new AI chips to accelerate drug discovery. Nvidia shares slipped 0.2% to $184.42 by 10:30 a.m. ET. Thermo Fisher Scientific will also collaborate with Nvidia on lab automation. The new site is expected to open by the end of March.
12 January 2026
····
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly shares rose about 0.7% Monday after announcing a $1 billion, five-year AI drug discovery lab partnership with Nvidia. The Bay Area facility, using Nvidia’s Vera Rubin chips, will open in March with teams from both firms. Investors are watching for updates from CEO David Ricks at the J.P. Morgan Healthcare Conference on Tuesday and Lilly’s earnings call on Feb. 4.
12 January 2026
······
Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly shares fell 1.99% to $1,063.56 Friday, trailing a record-setting S&P 500. Amazon Pharmacy began selling Novo Nordisk’s Wegovy pill for $149 a month, raising concerns about pricing pressure in obesity drugs. Lilly is set to address investors at the J.P. Morgan Healthcare Conference on Tuesday.
11 January 2026
······
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

U.S. healthcare stocks fell this week, with the XLV ETF down 0.5% to $157.31, even as the S&P 500 hit a record high. Two biotech firms, Eikon Therapeutics and Veradermics, filed for IPOs. Healthcare M&A value rose 56% in 2025 to $403 billion, despite fewer deals. Insmed reported preliminary 2025 ARIKAYCE sales of $433.8 million and set a 2026 revenue target of $450–470 million.
10 January 2026
···
Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

Eli Lilly shares fell 2% to $1,063.56 Friday, extending a two-day decline and lagging the broader market. The drop followed late-stage trial results for a Zepbound-Taltz drug combo and news of a $1.2 billion deal to buy Ventyx Biosciences. A Form 4 filing showed Lilly Endowment sold 292,148 shares on January 7. Lilly will present at the J.P. Morgan Healthcare Conference on January 13.
10 January 2026
···
Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Schrödinger will integrate Eli Lilly’s AI drug discovery platform, TuneLab, into its LiveDesign software, giving biotech teams direct access to Lilly’s predictive models. Revvity and Benchling also announced deals to offer TuneLab through their platforms. Lilly and Revvity will jointly fund access for select users, using federated learning to protect data. BigHat Biosciences will collaborate with Lilly to improve antibody developability models.
10 January 2026
····
Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Eli Lilly shares fell nearly 2% to $1,063.56 Friday, logging a second straight decline after hitting a 52-week high Thursday. The drop followed news that its Zepbound-Taltz drug combo outperformed Taltz alone in a late-stage trial, and a $1.2 billion deal to buy Ventyx Biosciences. Investors are watching for pricing pressures in Europe and key support near $1,060. Lilly’s next earnings call is Feb. 4.
9 January 2026
·
Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly shares fell 2.1% after hours to $1,085.19 following late-stage data showing its Zepbound-Taltz combo met dual goals in 31.7% of psoriatic arthritis patients, versus 0.8% for Taltz alone. The company also agreed to buy Ventyx Biosciences for $1.2 billion and disclosed a $322.4 million share sale by Lilly Endowment Inc. Investors await updates at the J.P. Morgan Healthcare Conference next week.
9 January 2026
··
Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

Eli Lilly shares rose 4.1% premarket to $1,108.09 after the company agreed to buy Ventyx Biosciences for $1.2 billion in cash. The deal, expected to close in the first half of 2026, adds oral inflammation drugs to Lilly’s pipeline. Lilly will pay $14 per Ventyx share, a 62% premium to its recent average. Investors are watching for details on pipeline progress and spending ahead of Lilly’s next earnings call.
8 January 2026
·
Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Eli Lilly agreed to acquire Ventyx Biosciences for $14 per share in cash, valuing the company at about $1.2 billion. Ventyx shares closed up 37% at $13.81, while Lilly rose 4%. The deal is expected to close in the first half of 2026, pending shareholder approval. Investors await proxy filings and Lilly’s next earnings call for further details.
7 January 2026
···
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

Eli Lilly shares rose 4.1% to $1,108.09 after the company agreed to acquire Ventyx Biosciences for $1.2 billion in cash. Ventyx holders will receive $14 per share, a 62% premium to its 30-day VWAP. The deal is expected to close in the first half of 2026, pending regulatory and shareholder approval. Lilly also announced a multi-year obesity drug partnership with Nimbus Therapeutics.
7 January 2026
···
Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage

Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage

Eli Lilly shares rose 3.3% to $1,099.44 after reports it is in advanced talks to buy Ventyx Biosciences for over $1 billion, according to the Wall Street Journal. The news follows Lilly’s new obesity-drug partnership with Nimbus and comes as Novo Nordisk launches an oral Wegovy pill in the U.S. Investors await updates at next week’s J.P. Morgan healthcare conference and Lilly’s upcoming earnings call.
7 January 2026
·
Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly shares rose about 1.6% Tuesday after Nimbus Therapeutics announced a deal to develop an oral obesity drug with the company. Nimbus will receive $55 million upfront and could get up to $1.3 billion in total payments plus royalties. The agreement follows Novo Nordisk’s U.S. launch of its $149-a-month Wegovy pill, intensifying focus on oral weight-loss treatments.
6 January 2026
··
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly shares fell 3.6% to $1,041.51 in after-hours trading Monday after Novo Nordisk launched a pill version of its Wegovy weight-loss drug in the U.S. Novo’s shares rose 5.2% as investors reacted to new pricing and distribution details. Lilly’s stock traded as low as $1,034 earlier in the session. Investors await commentary at the J.P. Morgan Healthcare Conference and Lilly’s earnings call.
6 January 2026
···
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 after Novo Nordisk began U.S. sales of its Wegovy pill at $149 a month for self-paying patients. Structure’s stock had reached $72.02 earlier in the session before retreating. Investors await updates on its Phase 3 plans and next earnings report, expected Feb. 26.
5 January 2026
·····
1 … 4 5 6 7 8 … 13

Stock Market Today

  • USDA Boosts Argentina Soybean Production, Weighing on Soybean Prices
    June 12, 2026, 8:43 AM EDT. Soybeans fell modestly on Thursday, with cash prices down 7 3/4 cents to $10.61 1/2 amid an increase in Argentina's production forecast by the U.S. Department of Agriculture (USDA). The USDA raised Argentina's soybean output by 2 million metric tons (MMT) to 50 MMT, contributing to a global supply surplus and higher world ending stocks for 2025/26. U.S. export sales for soybeans declined 23.7% week-on-week but remained above last year's levels. Soymeal futures showed mixed results, while soy oil futures dropped. Brazil's production was steady at 180 MMT. The USDA's World Agricultural Supply and Demand Estimates (WASDE) report signaled stable U.S. old and new crop stocks, with a slight internal adjustment. Market participants are adjusting to the increased international supplies amid ongoing trade demand.

Latest articles

Richtech Robotics Stock Drops After Restatement Warning

Richtech Robotics Stock Drops After Restatement Warning

12 June 2026
Richtech Robotics plunged up to 10% premarket after disclosing that audited financial statements for 2024, 2025, and multiple quarters should not be relied upon, citing errors tied to warrant liabilities, a SEPA, and restricted stock awards; investors now await amended filings and Nasdaq compliance updates as valuation remains uncertain.
National Grid Shares Slip After UK Grid Reform; £70bn Plan in Spotlight

National Grid Shares Slip After UK Grid Reform; £70bn Plan in Spotlight

12 June 2026
National Grid shares slipped 0.41% to 1,203p, underperforming the FTSE 100, as investors weighed the impact of UK grid-connection reforms that boost long-term investment prospects but increase execution risk; next catalysts are the July AGM/dividend vote and November half-year results, with analysts’ median 12-month target at 1,388.5p, about 15% above current levels.
Go toTop